ClinicalTrialsFinder
RecruitingNCT06512259

AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.

Sponsor

AlloSource

Enrollment

200 participants

Start Date

Oct 19, 2023

Study Type

OBSERVATIONAL

Conditions

Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy

Summary

This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;
  • Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;
  • Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.

Exclusion Criteria3

  • Patients must not meet any of the following criteria to be considered for this clinical trial:
  • Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
  • Did not have post-operative evaluations at the clinical site.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAlloMend® Acellular Dermal Matrix allograft

AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.

Locations(1)

Alan H. Chen Surgical Associates, PC

Joliet, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06512259